Introduction {#Sec1}
============

The carcinoembryonic antigen (CEA) gene family belongs to the immunoglobulin superfamily \[[@CR1]\] and comprises of 29 genes that are located closely together on the long arm of chromosome 19 \[[@CR2]\]. CEA (CD66e and CEACAM5) is a complex, highly glycosylated macromolecule. It was first described in 1965 as a gastrointestinal oncofetal protein that is expressed during fetal life but not in healthy adults, re-emerging in cancer \[[@CR3]\]. It is now accepted that this original description does not apply to CEA. Although CEA is overexpressed in a majority of carcinomas, including those of the gastrointestinal, respiratory, and genitourinary tracts as well as in breast cancers, it is also expressed in normal adult tissue \[[@CR4]\]. Among the main proteins of the CEA family, CEA is the only one that has been characterized as a useful tumor marker in cancer patients. Increased CEA levels are the first indicator of recurrent disease \[[@CR5], [@CR6]\], and serum CEA levels are also used as a prognostic indicator in colorectal cancer patients.

CEACAM6 (CD66c, NCA-90) is a member of the CEA family. It is expressed on granulocytes and on the epithelium of various organs \[[@CR7]\]. CEACAM6 is also expressed in many human cancers and is observed in the sera of cancer patients \[[@CR4], [@CR8]--[@CR10]\]. Although CEACAM6 belongs to CEA family, the levels of CEACAM6 do not correlate with the expression of CEA \[[@CR10]\]. CEACAM6 expression in colorectal cancer inversely correlates with cellular differentiation \[[@CR11]\] and is an independent prognostic factor associated with a higher risk of colorectal cancer relapse \[[@CR12]\]. CEACAM6 exhibits homotypic binding with other members of the CEA family and heterotypic interactions with integrin receptors \[[@CR13]\]. CEACAM6 has been shown to play a role in cell adhesion, invasion, and metastasis. Antibodies that target the N-domain of CEACAM6 interfere with cell-cell interactions \[[@CR14]\]. The apoptotic response in normal cells to inadequate or inappropriate intercellular or matrix attachment is termed anoikis \[[@CR15]\]. While anoikis is thought to maintain tissue order within multisystem organisms by preventing ectopic cellular proliferation, resistance to anoikis is a characteristic of tumor cells and has been reported to contribute to primary tumorigenesis and metastasis in a number of cancers \[[@CR16]--[@CR18]\]. CEACAM6 overexpression markedly inhibits anoikis \[[@CR19]\]. CEACAM6 gene silencing by small interfering RNA increases susceptibility to caspase-mediated anoikis, decreases Akt phosphorylation under anchorage-independent growth conditions, and inhibits metastatic potential \[[@CR20]\]. Overexpression of CEACAM6 is also associated with enhanced Src-dependent cellular invasion \[[@CR21]\].

A variety of tumor markers is widely used to detect early cancers and recurrence or metastasis after curative management for many types of malignancies. The metastatic process consists of a series of sequential steps \[[@CR22]\]. Eradication of metastatic disease is critical for achieving survival in most cancer patients. A relatively high rate of CEACAM6-positive reactivity has been demonstrated in the sera of patients with lung cancer, hepatocellular carcinoma, pancreatic cancer, breast cancer, and colorectal cancer \[[@CR10]\]. It has also been demonstrated that the expression levels of CEACAM6 are higher than those of CEA in malignant tumors including breast cancer, lung cancer, prostate cancer, colon cancer, pancreatic cancer, and ovarian cancer. Moreover, the level of CEACAM6 in liver metastases of colon cancers was higher than in many corresponding primary tumors \[[@CR23]\]. Thus, CEACAM6 may be more effective than CEA as a marker for detecting early cancers and cancer relapse or metastasis. CEACAM6 has also been shown to be involved in the metastatic process and therefore it represents a potential therapeutic target for the control of metastasis.

We generated a new monoclonal antibody (mAb) AP11, which recognizes human CEACAM6. We used AP11 to analyze CEACAM6 expression by immunohistochemistry in 282 human tumor tissues. The goals of the current study were to (1) demonstrate the use of paraffin-embedded tissue blocks and cell lines to confirm the expression pattern of AP11-reactive CEACAM6 in different types of solid tumors, and (2) develop evidence that supports the utility of CEACAM6 as a tumor marker.

Materials and methods {#Sec2}
=====================

Production of monoclonal antibody {#Sec3}
---------------------------------

Six week-old BALB/c mice were immunized intraperitoneally with 10^7^ phytohemagglutinin (PHA)-activated human peripheral blood mononuclear cells (PBMCs) at 2-week intervals for 2 months. Spleens were removed, and 10^8^ spleen cells were fused with 10^7^ SP2/0-Ag14 mouse myeloma cells using polyethylene glycol (PEG 4000, Rathway, NL, USA). The cell hybrids were cultured in flat-bottom microculture trays at 37 °C in an atmosphere of humidified air containing 5 % CO~2~, in hypoxanthine-aminopterin-thymidine (HAT) selection media (Sigma-Aldrich, USA). After 10 days, culture supernatants were harvested and tested for reactivity to human granulocytes by indirect immunofluorescence and flow cytometry (Coulter, USA). One of the resulting hybridoma clones whose supernatants were reactive to human granulocytes was named AP11. AP11 was subcloned by limiting dilution, and the culture supernatants of the sub-clones were tested for antibody production.

Cloning of CEACAM6-hFc {#Sec4}
----------------------

Deletion mutants of CEACAM6 cDNA were derived from human lung adenocarcinoma cell line A549 by RT-PCR and ligated into pGEM-T vector (Promega, USA). The CEACAM6 cDNA was inserted into the mammalian expression vector pcDNA3.1 using restriction endonucleases *EcoR*I. The CEACAM6 cDNA fragment and human Fc cDNA were inserted into the mammalian secretion vector pSecTag (Invitrogen, USA) using *Hind*III, *EcoR*V, and *Xho*I. A day before transfection, 293T cells were cultured and maintained at 1 × 10^6^ cells/mL density on six-well plates with 3 mL DMEM medium containing 10 % heat-inactivated fetal bovine serum (FBS; GIBCO, Invitrogen, USA), incubated at 37 °C with 5 % CO~2~. The dishes were 80 % confluent on the day of transfection. Deletion mutants of CEACAM6 in pSecTag vector were transiently transfected into 293T cell by using Effectene transfection reagent kit (QIAGEN, Germany). Three days later, the resulting supernatant was tested by ELISA assay.

ELISA method {#Sec5}
------------

Deletion mutants of CEACAM6 recombinant protein were tested for reactivity against AP11, goat anti-human Fc fragment, and human immunoglobulin by ELISA. Microtitration plates (96-well, Maxisorp; Nunc, Denmark) were coated with 100 ng/well of goat anti-human Fc fragment in 1× phosphate-buffered saline (PBS) and incubated with culture supernatant for 1 h at 37 °C, followed by three washes. Next, the plates were treated with the CEACAM6 recombinant protein supernatant (100 μL) and the recombinant proteins of other CEACAM families for 1 h at 37 °C, washed three times and then treated with anti CEACAM6-horseradish peroxidase (HRP) for 30 min at 37 °C. Following three washes, the plate was incubated with 50 mL/well TMB (3, 3′, 5, 5′-tetramethylbenzidine) substrate solution (Sigma-Aldrich, USA) for 10 min at room temperature. Substrate development was stopped by the addition of 2 N sulfuric acid, and the absorbance was measured at 450 nm using an ELISA reader (SpectraMax M5, Molecular devices, USA).

Western blot analysis {#Sec6}
---------------------

Peripheral blood neutrophils from healthy donors were lysed in lysis buffer (1 % NP-40 in 50 mM Tris-HCl, pH 7.4, 50 mM EDTA, and 1 mM PMSF). After centrifugation to remove cell debris, the supernatant was subjected to 8 % SDS-PAGE under non-reducing condition with appropriate molecular weight markers. After electrophoretic transfer of the proteins to nitrocellulose membrane, the membrane was blocked with 5 % skim milk in Tris-buffered saline (10 mM Tris-HCl, 150 mM NaCl, pH 7.6) containing 0.05 % Tween-20. The membrane was incubated with AP11, followed by peroxidase-conjugated goat anti-mouse IgG (Sigma, Saint Louis, 1:5000 dilution in blocking solution). Immunoreactive proteins were visualized using the ECL chemoluminescence detection system (Amersham Pharmaciam, Sweden).

Tissue samples and immunohistochemical staining {#Sec7}
-----------------------------------------------

This study was approved by the ethics committee of Chungbuk National University. Written informed consent was obtained from the patients and patients' families before the beginning of the study. Tissue samples from 282 human malignant tumors to 157 normal tissues were obtained from the surgical pathology files of Chungbuk National University Hospital and Korean Cancer Center as listed in Table [1](#Tab1){ref-type="table"}. All tissues had been fixed in 10 % formalin and embedded in paraffin. Antigen retrieval was performed by microwave heating in 10 mM sodium citrate, pH 6.0 (Dako, Denmark) for 15 min. Indirect immunoperoxidase method was used.Table 1Organ type and number of tumor and normal tissues examined in this studyOrganTumorNormalStomach3820 Adenocarcinoma28 High-grade GED5 Low-grade GED5Colorectum2910 Adenocarcinoma19 Tubular adenoma5 Hyperplastic polyp5Pancreatic (adenocarcinoma)22Liver (hepatocellular carcinoma)1710Lung5830 Adenocarcinoma18 Squamous cell carcinoma20 Small cell carcinoma20Ovary1610 Mucinous carcinoma8 Serous carcinoma6 Endometrioid carcinoma1 Clear cell carcinoma1Kidney (renal cell carcinoma)2210Bladder3315 Urothelial carcinoma30 Adenocarcinoma3Prostate (adenocarcinoma)88Urethra (adenocarcinoma)11Breast (invasive ductal carcinoma)99Thyroid (papillary carcinoma)88Skin (melanoma)44Bone3720 Osteosarcoma32 Giant cell tumor5Total282157*N* number of samples examined

The sections were incubated overnight with primary mAb (AP11, 1:1000) in blocking buffer (4 % skim milk, 0.1 % Tween-20 in 1× PBS) at 4 °C. On the next day, the sections were washed and incubated with biotinylated goat anti-mouse IgG and HRP-conjugated streptavidin (Dako, Denmark) for 20 min at room temperature. 3,3′-Diaminobenzidine (Sigma, Saint Louis, USA) was used as chromogen. The pattern of reactivity was analyzed based on serial hematoxylin-eosin-stained sections. CEACAM6 expression detected by AP11 was defined as positive when staining was observed along the luminal cell border or in the cytoplasm in ≥10 % of cells in the whole tissue section.

Results {#Sec8}
=======

Characterization of the AP11 target antigen {#Sec9}
-------------------------------------------

When the peripheral blood cells were analyzed by flow cytometry using AP11, granulocytes exhibited a high level of reactivity to AP11, indicating the expression of AP11 antigen, whereas lymphocytes and monocytes were negative for AP11 (Fig. [1](#Fig1){ref-type="fig"}). Using Western blot with neutrophil lysates, the molecular weight of the AP11 antigen was shown to be approximately 90 kDa (Fig. [2](#Fig2){ref-type="fig"}). Enzyme-based immunoassay determined the isotype of AP11 to be IgM. In a separate experiment involving flow cytometric analysis, AP11 was confirmed to be highly specific to CEACAM6 (CD66c) not to cross-react with CD66b (Fig. [3](#Fig3){ref-type="fig"}).Fig. 1In-flow cytometric analysis of peripheral blood using mAb AP11. Granulocytes show a high level of reactivity to mAb AP11. Granulocytes (*c*) were gated to determine the CD13 and AP11 positivity (*upper right panel*). *Lower panels* show fluorescence for AP11 for lymphocytes (*a*), monocytes (*b*), and granulocytes, respectivelyFig. 2Western blot analysis demonstrating that AP11 antigen detects a protein of approximately 90 kDa in neutrophil lysatesFig. 3Flow cytometry result showing that AP11 is specific for CEACAM6 and does not cross-react with CD66b in a CHO transfection study. **a** CD66b transfection. **b** CEACAM6 transfection. (*N.C.* negative control)

Epitope mapping of mAb AP11 {#Sec10}
---------------------------

Human CEACAM6 consists of an extracellular domain (ECD) containing one N-terminal V-type Ig-like domain and two C2-type Ig-like domains, and a hydrophobic C-terminal propeptide. The GPI membrane anchor is attached at the C-terminus following cleavage of the propeptide \[[@CR24]\]. To identify the epitope for human CEACAM6 recombinant protein that binds to AP11, epitope mapping was performed using human Fc fusion protein gene constructs encoding CEACAM6 deletion mutants (Fig. [4a](#Fig4){ref-type="fig"}). Sandwich ELISA results showed that AP11 successfully recognized full-length protein and BI/*BamH*I/lig protein, whereas HKP/*Hind*III/*pst*I/lig protein was not recognized by AP11 (Fig. [4b](#Fig4){ref-type="fig"}). These results revealed that the AP11 epitope is located in the functional N-domain of CEACAM6. When ELISA was performed to analyze the cross-reactivity of AP11 with members of the CEACAM family, AP11 was found to be reactive only with CEACAM6 fusion protein, indicating specificity of AP11 for CEACAM6 (Fig. [4c](#Fig4){ref-type="fig"}).Fig. 4**a** Schematic diagram of recombinant CEACAM6-hFC fusion genes. The constructs for CEACAM6-hFc fusion proteins deleted in the extracellular domain were cloned to identify the AP11 epitope. **b** Sandwich ELISA performed using goat anti-hFc specific antibody and AP11 for the detection of various CEACAM6-hFc fusion proteins. The results identified N-domain of CEACAM6 as the AP11-reactive epitope. **c** ELISA results showing that AP11 only recognizes CEACAM6 among families of hFc fusion proteins, when checked for cross-reactivity using AP11 (*y*-axis, optical density)

CEACAM6 expression in various tumor and normal tissues {#Sec11}
------------------------------------------------------

Of the gastric adenocarcinomas, 24 of 28 (86 %) showed CEACAM6 expression (Fig. [5a](#Fig5){ref-type="fig"}). In contrast, none of the cases of dysplasia including both high- and low-grade lesions expressed CEACAM6. These results suggest that AP11 differentiates between gastric cancer and its premalignant precursors.Fig. 5CEACAM6 immunoreactivity in **a** gastric adenocarcinoma, **b** colorectal adenocarcinoma, **c** pancreatic adenocarcinoma, **d** lung adenocarcinoma, **e** ovarian mucinous carcinoma, and **f** urinary bladder adenocarcinoma. (Magnification, ×200)

Most colorectal adenocarcinomas (18 out of 19 cases) were positive for CEACAM6 (Fig. [5b](#Fig5){ref-type="fig"}). Four of five tubular adenomas (80 %) and four of five hyperplastic polyps (80 %) stained positive for CEACAM6. In contrast to the stomach, most premalignant lesions were also positive. Both cases of pancreatic adenocarcinoma expressed CEACAM6 (Fig. [5c](#Fig5){ref-type="fig"}), whereas only 6 out of 17 hepatocellular carcinoma samples were CEACAM6 positive.

Overall, 47 % of the lung cancer samples showed CEACAM6 expression. CEACAM6 was not expressed in small cell lung cancer (SCLC) but in 71 % of non-small cell lung cancer (NSCLC). Of the NSCLCs, lung adenocarcinomas more often showed CEACAM6 expression than squamous cell carcinomas (Fig. [5d](#Fig5){ref-type="fig"}). This expression pattern suggests that AP11 can effectively distinguish between NSCLCs and SCLCs.

In ovarian cancers, CEACAM6 expression was highest in mucinous carcinoma (seven out of eight samples, 88 %) (Fig. [5e](#Fig5){ref-type="fig"}), whereas only 17 % of serous carcinoma samples were positive for CEACAM6. None of the endometrioid and clear cell cancers exhibited CEACAM6 expression.

Adenocarcinomas from the urinary bladder (Fig. [5f](#Fig5){ref-type="fig"}) and urethra were CEACAM6 positive, whereas all prostate adenocarcinomas were CEACAM6 negative. CEACAM6 was expressed in a subset of clear renal cell carcinomas and urothelial carcinomas (14 and 13 %, respectively).

Only one out of nine ductal carcinomas of the breast showed CEACAM6 expression (Fig. [6a](#Fig6){ref-type="fig"}), whereas no papillary thyroid carcinoma displayed CEACAM6 expression (Fig. [6b](#Fig6){ref-type="fig"}). Of the 4 melanomas, 32 osteosarcomas, and 5 giant cell tumors of the bone, none expressed CEACAM6 (Table [2](#Tab2){ref-type="table"}).Fig. 6CEACAM6 is not expressed in **a** invasive ductal carcinoma of breast and **b** papillary thyroid carcinoma. (Magnification, ×200)Table 2Profile of CEACAM6-positive immunostaining in various tumor tissuesOrganDiagnosis*N* (282)Positive *N* (%)StomachAdenocarcinoma2824 (86)High-grade GED50 (0)Low-grade GED50 (0)ColorectumAdenocarcinoma1918 (95)Tubular adenoma54 (80)Hyperplastic polyp54 (80)PancreasAdenocarcinoma22 (100)LiverHepatocellular carcinoma176 (35)LungAdenocarcinoma1815 (83)Squamous cell carcinoma2012 (60)Small cell carcinoma200 (0)OvaryMucinous carcinoma87 (88)Serous carcinoma61 (17)Endometrioid carcinoma10 (0)Clear cell carcinoma10 (0)KidneyRenal cell carcinoma223 (14)BladderUrothelial carcinoma304 (13)Adenocarcinoma33 (100)ProstateAdenocarcinoma80 (0)UrethraAdenocarcinoma11 (100)BreastInvasive ductal carcinoma91 (11)ThyroidPapillary carcinoma80 (0)SkinMelanoma40 (0)BoneOsteosarcoma320 (0)BoneGiant cell tumor50 (0)*GED* gastric epithelial dysplasia, *N* number of samples examined

None of normal tissue samples from the stomach, colorectum, pancreas, liver, lung, breast, thyroid, ovary, kidney, bladder, prostate, urethra, skin, and bone showed CEACAM6 immunoreactivity.

Discussion {#Sec12}
==========

CEACAM6 (CD66c, NCA-90) is a 90-kDa glycosylphosphatidylinositol (GPI)-linked glycoprotein that is overexpressed in a variety of gastrointestinal malignancies \[[@CR12], [@CR25]\]. Despite lacking a transmembrane or intracellular domain, CEACAM6 influences intracellular signal transduction and plays an important role in the progression of gastrointestinal cancer \[[@CR8], [@CR11], [@CR25]\]. To date, pancreatic and colorectal cancers have been the primary focus of CEACAM6 expression studies \[[@CR8], [@CR9], [@CR12], [@CR18]--[@CR20], [@CR25]--[@CR28]\]. We show that CEACAM6 is expressed in particular in mucin-producing, gland-forming adenocarcinomas that arise in the gastrointestinal tract, lung, and ovary. Blumenthal et al. explored the expression of CEACAM6 and CEA in a panel of solid tumors, including breast, lung, ovary, prostate, pancreas, and colorectal cancers, using tissue microarrays \[[@CR23]\]. Their results show that CEACAM6 is more strongly expressed than CEA, and that expression of CEACAM6 is strongly dependent on the histologic tumor type. CEACAM6 expression in some subtypes was 2--4-fold stronger than in normal tissue, while in others, expression was similar to that in non-neoplastic tissues. Adenocarcinomas of the lung expressed CEACAM6 more strongly than squamous cell carcinomas. CEACAM6 expression in large cell and poorly differentiated squamous carcinomas was similar to non-neoplastic lung tissue, and SCLC also expressed CEACAM6. We did not detect CEACAM6 expression in SCLC, while adenocarcinomas and squamous cell carcinomas frequently expressed CEACAM6 (83 and 60 %, respectively). These findings point indicate that AP11 stained CEACAM6 is a marker that differentiates between SCLC and NSCLC in tissue samples.

CEACAM6 is highly expressed in ovarian mucinous neoplasms. Litkouhi et al. reported that CEACAM6 is expressed at higher levels in borderline mucinous neoplasms and invasive mucinous carcinomas than in serous ovarian neoplasms \[[@CR29]\]. Consistent with this, we found that seven out of eight mucinous carcinomas (88 %) but only one case of serous carcinoma (17 %) stained positive for CEACAM6 using the AP11 antibody. Taken together, these data suggest that CEACMA6 may be a potential marker for mucinous ovarian carcinomas.

Kinugasa et al. investigated CEACAM6 expression in gastric adenocarcinoma and carcinoma cell lines in comparison to adjacent normal gastric mucosa using reverse transcription-polymerase chain reaction (RT-PCR). They found higher CEACAM6 transcript levels in gastric cancer tissues compared to adjacent normal tissues, and CEACAM6 transcripts were detectable in 92 % (11/12) and 25 % (3/12) of gastric cancer and normal gastric mucosa samples, respectively \[[@CR30]\]. Yasui et al. demonstrated that CEACAM6 expression is upregulated in gastric cancer compared to normal gastric epithelia using serial analysis of gene expression (SAGE) \[[@CR31]\]. Kodera et al. showed similar upregulation of CEA and CEACAM6 in gastric carcinomas using Northern blot analysis \[[@CR25]\]. We observed differential expression of the AP11-reactive CEACAM6 epitope in invasive gastric cancer and dysplastic lesions. We observed high expression (86 %) in gastric cancer, which is consistent with previous reports, but no or low CEACAM6 expression in dysplasia. Taken together, these findings suggest that CEACAM6 is a potentially useful marker for gastric cancer and differentiates between carcinomas and gastric dysplasia.

Upregulation of CEACAM6 expression in hyperplastic polyps and early adenomas indicates that it is an early event in the development of colorectal cancer. Schozel et al. found CEACAM6 expression in all 25 examined colonic polyps \[[@CR8]\]. We observed expression of CEACMA6 in most tubular adenomas (80 %) and hyperplastic polyps (80 %). A prognostic significance of CEA expression for different types of carcinoma has not been established \[[@CR32]--[@CR35]\]. In contrast, expression of CEACAM6 in colorectal cancer tissue is significantly associated with poor prognosis \[[@CR12]\]. Tissue expression of CEACAM6 in liver metastases of colorectal cancer is higher than that in primary colorectal cancer \[[@CR23]\]. However, in breast, colon, or lung carcinomas, CEACAM6 expression is similar to that in their lymph node metastases \[[@CR23]\]. CEACAM6 plays an important role in migration, invasion, and adhesion, crucial steps for the metastatic spread of cancer cells to secondary tissue sites other than lymph nodes and potential targets for new therapeutic modalities \[[@CR36]--[@CR38]\].

Pancreatic cancer has been the most extensively studied neoplasm with respect to CEACAM6 expression \[[@CR19]--[@CR21], [@CR23], [@CR26]--[@CR28]\]. The majority of invasive pancreatic adenocarcinomas express CEACAM6, and CEACAM6-negative patients may represent a subgroup of patients who survive longer after surgical resection \[[@CR28]\]. The level of CEACAM6 expression influences the cellular invasiveness of pancreatic adenocarcinomas in a c-Src-dependent manner. Overexpression of CEACAM6 enhances cellular invasion, whereas CEACAM6 knockdown attenuates invasiveness \[[@CR21]\]. CEACAM6 is an important determinant of malignant cellular behavior in pancreatic adenocarcinoma. Anoikis refers to the apoptotic response induced in normal cells by inadequate or inappropriate adhesion to a substrate \[[@CR15]\]. It is postulated that resistance to anoikis contributes to primary tumorigenesis and metastasis \[[@CR16]--[@CR18]\]. Anoikis resistance is associated with increased CEACAM6 expression, and CEACAM6 gene silencing impairs anoikis resistance and inhibits the metastatic potential of pancreatic adenocarcinoma cells in vivo \[[@CR19]\]. CEACAM6 expression appears to be an early event in the progression to pancreatic cancer. In a previous study, half of the low-grade pancreatic intraepithelial neoplasia (PanIN) lesions examined demonstrated some positive staining for CEACAM6, whereas all PanIN3 lesions were CEACAM6 positive \[[@CR28]\].

The expression of CEACAM6 in atypical ductal hyperplasia of the breast (ADH) is strongly associated with the development of invasive breast cancer and might serve as a marker for its early diagnosis. It also represents a potential molecular target for the treatment of patients with precancerous lesions who express CEACAM6 to prevent the development of invasive breast cancer \[[@CR39]\]. In recent study, CEACAM6 was reported as predictive for endocrine therapy resistance and a unique mediator of migration and invasion of drug-resistant estrogen-deprived breast cancer cells \[[@CR40], [@CR41]\].

The level of CEACAM6 in the blood of normal individuals is higher (0.05 mg/L) than that of CEA (\<2 μg/L). It is therefore unlikely that CEACAM6 will be more useful than CEA as a serum marker \[[@CR4]\]. The expression of CEACAM6 in solid tumors is higher than that of CEA, which makes it a more promising target for antibody-based anti-metastatic and chemosensitizing therapy \[[@CR23]\].

In summary, we generated a new mAb, AP11, which recognizes CEACAM6, and evaluated its ability to be used as a tool to recognize CEACAM6 expression as a tumor marker in human cancer cells and tissues. AP11 recognizes CEACAM6 in formalin-fixed and paraffin-embedded tissues. CEACAM6 expression is high in particular in mucin-producing, gland-forming adenocarcinomas arising in the gastrointestinal tract, ovary, and NSCLCs. Thus, mAb AP11-stained CEACAM6 may serve as a marker for mucinous tumors.
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